EULAV Asset Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

EULAV Asset Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-500,000	Closed	-$1.28M	–	173
2024 Q2	$1.28M	Hold	500,000	–	–	0.03%	166
2024 Q1	$2.46M	Sell	500,000 -130,000	-21%	-$770K	0.07%	162
2023 Q4	$5.54M	Buy	630,000 +30,000	+5%	+$246K	0.17%	120
2023 Q3	$6.88M	Buy	600,000 +440,000	+275%	+$8.46M	0.25%	96
2023 Q2	$4.05M	Buy	160,000 +55,000	+52%	+$1.71M	0.15%	132
2023 Q1	$3.38M	Sell	105,000 -65,000	-38%	-$2.03M	0.13%	134
2022 Q4	$3.14M	Buy	+170,000	New	+$3.89M	0.13%	138

Other funds holding RVNC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

EULAV Asset Management's RVNC Position: Q3 2024 in Review

EULAV Asset Management sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2024, closing a stake of 500,000 shares — an estimated $1.28M sold.

EULAV Asset Management first reported a position in RVNC in Q4 2022 and held it in 7 quarters. The position peaked at $6.88M in Q3 2023. 201 funds tracked by Wall St. Rank hold RVNC as of Q3 2024.

EULAV Asset Management reported no remaining Revance Therapeutics, Inc. position as of Q3 2024 after selling out during the quarter.
EULAV Asset Management sold 500,000 Revance Therapeutics, Inc. shares in Q3 2024, an estimated $1.28M.
EULAV Asset Management first reported a position in Revance Therapeutics, Inc. in Q4 2022 and held it in 7 quarters.
EULAV Asset Management's Revance Therapeutics, Inc. position peaked at $6.88M in Q3 2023.
201 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2024.

Based on EULAV Asset Management's 13F filing for Q3 2024, filed 8 Nov 2024.